Omnicell, Inc. reported its financial results for the third quarter of 2025, revealing total revenues of $310.6 million, a 10% increase from $282.4 million in the same period last year. Product revenues rose by 12% to $177.5 million, driven primarily by growth in the XTExtend offering, while service revenues increased by 7% to $133.1 million, attributed to a larger installed customer base and pricing actions. For the nine months ended September 30, 2025, total revenues reached $870.9 million, up 8% from $805.4 million in the prior year.
The company's gross profit for the third quarter was $134.5 million, maintaining a gross margin of 43%, consistent with the previous year. However, total operating expenses increased by 9% to $126.3 million, primarily due to higher employee-related costs and freight expenses. Net income for the quarter was $5.5 million, or $0.12 per diluted share, down from $8.6 million, or $0.19 per diluted share, in the prior year. For the nine-month period, net income was $4.1 million, compared to a loss of $3.3 million in the same period last year.
Omnicell's balance sheet as of September 30, 2025, showed total assets of $1.95 billion, down from $2.12 billion at the end of 2024. Cash and cash equivalents decreased significantly to $180.1 million from $369.2 million, largely due to stock repurchases and the repayment of convertible senior notes. The company repurchased approximately 2.5 million shares of its common stock for $77.6 million during the nine months, completing its previous repurchase program.
In terms of operational metrics, Omnicell's employee headcount was approximately 3,600 as of September 30, 2025. The company continues to focus on expanding its market presence, particularly in the healthcare sector, where it aims to enhance medication management solutions. The company has also emphasized its commitment to research and development, with R&D expenses increasing by 3% to $66.1 million for the nine months ended September 30, 2025.
Looking ahead, Omnicell anticipates continued growth driven by the increasing demand for automation in medication management and the expansion of its product offerings. The company remains focused on addressing challenges in the healthcare sector, including labor shortages and budget constraints, which it believes will drive demand for its solutions. However, it also acknowledges potential risks related to market conditions, supply chain disruptions, and regulatory changes that could impact its operations and financial performance.
About OMNICELL, INC.
Omnicell designs and provides medication management automation, software workflows, and expert services for healthcare facilities. Its solutions enhance safety, efficiency, and patient adherence across inpatient, outpatient, and retail settings. Focused on the industry vision of the Autonomous Pharmacy, the company addresses challenges like labor shortages, medication errors, and rising drug costs, supporting healthcare providers worldwide with integrated, data-driven medication automation and optimization systems.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.